US 12,466,897 B2
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
Gregory L. Moore, Monrovia, CA (US); and Gregory Lazar, Pacifica, CA (US)
Assigned to Xencor, Inc., Pasadena, CA (US)
Filed by Xencor, Inc., Pasadena, CA (US)
Filed on Mar. 21, 2025, as Appl. No. 19/087,398.
Application 19/087,398 is a continuation of application No. 17/068,441, filed on Oct. 12, 2020.
Application 17/068,441 is a continuation of application No. 13/648,951, filed on Oct. 10, 2012, granted, now 10,851,178, issued on Dec. 1, 2020.
Application 13/648,951 is a continuation in part of application No. 13/568,028, filed on Aug. 6, 2012, abandoned.
Claims priority of provisional application 61/598,686, filed on Feb. 14, 2012.
Claims priority of provisional application 61/593,846, filed on Feb. 1, 2012.
Claims priority of provisional application 61/545,498, filed on Oct. 10, 2011.
Prior Publication US 2025/0230262 A1, Jul. 17, 2025
Int. Cl. C07K 16/46 (2006.01); C07K 16/00 (2006.01); C07K 14/52 (2006.01); C07K 14/525 (2006.01); C07K 14/535 (2006.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 14/745 (2006.01); C07K 14/755 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/468 (2013.01) [C07K 16/00 (2013.01); C07K 14/521 (2013.01); C07K 14/522 (2013.01); C07K 14/523 (2013.01); C07K 14/525 (2013.01); C07K 14/535 (2013.01); C07K 14/54 (2013.01); C07K 14/5428 (2013.01); C07K 14/5434 (2013.01); C07K 14/55 (2013.01); C07K 14/70521 (2013.01); C07K 14/7151 (2013.01); C07K 14/745 (2013.01); C07K 14/755 (2013.01); C07K 16/22 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/283 (2013.01); C07K 16/2878 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/94 (2013.01); C07K 2319/30 (2013.01)] 1 Claim
 
1. A composition comprising a variant human IgG1 Fc region comprising the amino acid substitutions L351K and T366K, wherein numbering is according to the EU index, and wherein said variant human IgG1 Fc region has at least 95% sequence identity to SEQ ID NO: 2.